EGFR and non-small cell lung carcinoma: In a meta-analysis of six original eligible studies including 871 NSCLC patients [29], patients BIM del+ had poor response to EGFR TKI therapy (p= 0.001, OR = 0.39; 95% CI = 0.23–0.67).